UnknownNot Applicable

Effects of Radioactive Iodine on the Immune System in Thyroid Cancer

Netherlands30 participantsStarted 2024-01-01

Plain-language summary

Blood will be drawn 1 month before and 2 month after regular radioactive iodine treatment. Monocytes will be isolated. The three main outcomes are whole blood counts, cytokine production upon in vitro stimulation of monocytes and in vitro ROS production by monocytes. These results are compared between patients treated in adjuvant setting and patients treated for persistent structural disease, and between pre- and post-treatment status.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Pathologically confirmed non-medullary thyroid cancer * Undergoing radioactive iodine treatment in an adjuvant setting or for persistent structural disease * Aged ≥ 18 years Exclusion Criteria: * Inflammatory or infectious comorbidities * Using medication interfering with the immune system * Pregnancy * A self-reported alcohol consumption of \>21 units per week * Other active malignancies, defined as malignancies not in complete remission for \<2 years * Previous systemic anti-cancer treatment such as chemotherapy, targeted therapy, radiotherapy or immunotherapy within 3 years before study procedures

What they're measuring

Whole blood counts

Timeframe: 2 months

Cytokine production upon monocyte stimulation

Timeframe: 2 months

Reactive oxygen species (ROS) production by monocytes

Timeframe: 2 months

Trial details

NCT IDNCT05989555

SponsorRadboud University Medical Center

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-06-01

Contact for this trial

Pepijn van Houten, M.D.

+31243614599 pepijn.vanhouten@radboudumc.nl

View on ClinicalTrials.gov More Thyroid Carcinoma, Nonmedullary trials